Samsung Biologics– tag –
-
Lonza Expands US Manufacturing with New Spray Drying Facility; Samsung Biologics Secures $262M European CDMO Deal
Endpoints News Switzerland, South Korea, USA Overview Lonza announced a significant expansion of its U.S. manufacturing capabilities with a new commercial spray drying facility in Bend, Oregon, projected for completion by 2029 and creati... -
Samsung Biologics Secures $262M Manufacturing Contract with European Pharma Amid Peptide Expansion and CDMO Capacity Growth
BioProcess International South Korea Overview On September 10, 2026, Samsung Biologics announced a $262 million manufacturing agreement with an undisclosed European pharmaceutical company. This substantial contract will further accelerat... -
Samsung Biologics Inks $262M Manufacturing Deal with European Pharma, Propelling Songdo Expansion and Exceeding $21.9 Billion in Cumulative Contracts
BioProcess International USA Overview Samsung Biologics has announced a $262 million manufacturing contract with a European pharmaceutical company, extending through the end of 2033. Production will occur at the company’s manufacturing b... -
US Trade Policy and BIOSECURE Act Drive Major Reshaping and Investment in Global ADC Manufacturing Landscape
Bioprocess Online USA Overview U.S. trade policy and the BIOSECURE Act are significantly reshaping the Antibody-Drug Conjugate (ADC) manufacturing landscape, spurring substantial investments in capacity across the U.S., Europe, and Asia.... -
Samsung Biologics to Acquire PolyPeptide Group for $1.8B, Expanding CDMO Capabilities into Peptide Therapeutics with $2.2B Capital Raise
Endpoints News South Korea Overview Samsung Biologics announced a capital raise of nearly $2.2 billion to fund its long-term growth strategy, including the acquisition of PolyPeptide Group for $1.8 billion. This acquisition will signific... -
Samsung Biologics Announces KRW 3 Trillion ($2.18B) Rights Offering to Fund PolyPeptide Group Acquisition and Bio Campus II Expansion, Strengthening CDMO Leadership
PR Newswire South Korea Overview Samsung Biologics has announced a substantial KRW 3 trillion (approximately $2.18 billion) rights offering to finance its acquisition of PolyPeptide Group and the expansion of its Bio Campus II. This stra... -
Samsung Biologics Expands to 845,000L Capacity with GSK Facility Acquisition; Lonza, Resilience Announce Major Investments Amidst CDMO Restructuring
DCAT Value Chain Insights USA, South Korea, Switzerland Overview The CDMO industry is undergoing unprecedented restructuring in 2026, driven by major strategic investments and M&A activities by leading players. Samsung Biologics acqu... -
Biologics CDMO Market to Reach $38.29 Billion by 2031, Fill-Finish Emerging as Key Segment
GlobeNewswire Global Overview This article provides an overview of a market research report from GlobeNewswire. The Biologics CDMO market is projected to grow from $27.13 billion in 2026 to $38.29 billion by 2031, exhibiting a CAGR of 7.... -
Perfusion Cell Culture Patents 2026: Top 5 Assignees Hold 79.2% Share, Hardware and Cell Line Engineering Dominate Claims
Patsnap Germany Overview A patent analysis based on mid-2026 data reveals that 79.2% of patent activity in perfusion and intensified cell culture technologies is concentrated among the top five assignees. These patents primarily cover ha... -
Perfusion Bioreactor Adoption Doubles to 65.8% Since 2016, Accelerating Shift to Continuous Biomanufacturing
synbio.intel USA Overview A BioPlan Associates survey from August 2026 reveals that single-use perfusion equipment usage has doubled to 65.8% across all production stages since 2016, indicating an accelerating shift towards continuous bi...
